Target- |
Mechanism- |
|
|
|
Inactive Indication- |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc.Singapore |
First Approval Date06 Feb 2025 |
/ Not yet recruitingEarly Phase 1IIT Study on the effect mechanism of Liuwei Anshen capsule in the treatment of insomnia (yin deficiency and fire hyperactivity with phlegm syndrome) based on the inflammation mediated microbial gut brain axis
100 Clinical Results associated with Chongqing Huasen Pharmaceutical Co., Ltd.
0 Patents (Medical) associated with Chongqing Huasen Pharmaceutical Co., Ltd.
100 Deals associated with Chongqing Huasen Pharmaceutical Co., Ltd.
100 Translational Medicine associated with Chongqing Huasen Pharmaceutical Co., Ltd.